Drug intelligence / Profile preview

LYC002

Development stage: Preclinical
Lead developer: Beijing LiangYuan Bioscience
Modality: Cytokines & Interferons → Recombinant Proteins and Enzymes
Administration: Subcutaneous

Overview

LYC002 is a lymph node-targeted biologic therapy being developed by Beijing Liangyuan Pharmaceutical Research (Liangyuan Bio) for the treatment of neutropenia (granulocytopenia). The drug utilizes a specialized biomacromolecule delivery platform to deliver granulocyte colony-stimulating factor (G-CSF) specifically to the lymph nodes. This targeted approach is designed to enhance the production and maturation of neutrophils more effectively than conventional G-CSF treatments. As of late 2024, LYC002 is in the IND-enabling phase of development, with an Investigational New Drug (IND) application filing anticipated in September 2026.

Targets

CSF3R (Granulocyte colony-stimulating factor receptor)

Beyond the preview

Go deeper on LYC002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LYC002.

Explore the full profile